Sanofi $SNY Position Cut by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA trimmed its holdings in shares of Sanofi (NASDAQ:SNY) by 5.5% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 483,579 shares of the company’s stock after selling 28,157 shares during the period. Pictet Asset Management Holding SA’s holdings in Sanofi were worth $19,701,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in SNY. AlphaCentric Advisors LLC boosted its stake in shares of Sanofi by 5.2% during the 3rd quarter. AlphaCentric Advisors LLC now owns 15,345 shares of the company’s stock worth $633,000 after acquiring an additional 755 shares in the last quarter. Asset One Wealth Management LLC bought a new position in shares of Sanofi in the 3rd quarter valued at approximately $544,000. International Assets Investment Management LLC acquired a new stake in Sanofi in the 3rd quarter worth approximately $269,000. Genesis Private Wealth LLC lifted its holdings in Sanofi by 10.2% in the 3rd quarter. Genesis Private Wealth LLC now owns 8,426 shares of the company’s stock worth $347,000 after purchasing an additional 782 shares during the last quarter. Finally, Pzena Investment Management LLC boosted its position in Sanofi by 348.2% during the third quarter. Pzena Investment Management LLC now owns 113,396 shares of the company’s stock worth $4,675,000 after purchasing an additional 88,094 shares during the period. Institutional investors and hedge funds own 14.03% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. UBS Group reiterated a “neutral” rating on shares of Sanofi in a report on Thursday, September 17th. Berenberg Bank reissued a “buy” rating on shares of Sanofi in a research report on Monday, October 5th. Deutsche Bank restated a “buy” rating on shares of Sanofi in a research note on Tuesday, September 29th. DZ Bank reaffirmed a “buy” rating on shares of Sanofi in a report on Friday, July 31st. Finally, Wolfe Research assumed coverage on shares of Sanofi in a research note on Friday, October 9th. They issued a “peer perform” rating on the stock. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and twelve have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $53.00.

Sanofi Trading Up 0.4%

Sanofi stock opened at $48.43 on Thursday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.27 and a current ratio of 1.12. The business’s 50-day simple moving average is $42.52 and its 200-day simple moving average is $44.37. The firm has a market capitalization of $117.41 billion, a PE ratio of 23.98, a PEG ratio of 1.32 and a beta of 0.31. Sanofi has a 52 week low of $39.07 and a 52 week high of $52.68.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 30th. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.56 by $0.48. The firm had revenue of $17.25 billion during the quarter, compared to the consensus estimate of $14.30 billion. Sanofi had a return on equity of 15.16% and a net margin of 8.70%. The firm’s revenue for the quarter was up 16.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.91 EPS. Equities research analysts forecast that Sanofi will post 5.07 earnings per share for the current year.

Sanofi Company Profile

Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973.